5 Key Takeaways

• 1

  Sura vec, an anti-VEGF gene therapy, shows promise in treating nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME).

• 2

  The ALTITUDE trial demonstrated significant improvements in diabetic retinopathy severity scores (DRSS) with sura vec compared to control groups over two years.

• 3

  Patients receiving sura vec had a lower rate of DRSS worsening and higher rates of improvement compared to historical controls from Protocol W.

• 4

  Sura vec was well tolerated, with manageable side effects, particularly when combined with a short course of topical steroids.

• 5

  The findings support the need for a pivotal trial to further evaluate the efficacy and safety of suprachoroidal sura vec in NPDR patients.